Nuclear AR-V7 is a strong predictive biomarker of resistance to AR-targeted therapies2,3 like abiraterone, enzalutamide, and apalutamide

AR-V7 is a splice variant of the androgen receptor (AR) that lacks the ligand binding domain4

AR-V7 variants are resistant to abiraterone and enzalutamide1,5,6

The percentage of mCRPC patients with the AR-V7 splice variant (AR-V7+) increases with continued exposure to AR-targeted therapies4

The presence of any nuclear AR-V7 signals resistance to AR-targeted therapies and is associated with rapid disease progression and shorter cancer-specific survival1,4-6

In mCRPC, testing for AR-V7 can identify patients who will not respond to AR-targeted therapy4

AR-V7 assays with nuclear specificity deliver the highest possible accuracy5

1 Cytoplasmic AR-V7 translocates into the nucleus

2 Nuclear AR-V7 binds to DNA

3 Transcription of tumor growth genes

4 Translation of tumor growth gene mRNA into protein

Since some AR-V7 protein does not translocate to the nucleus AND some mRNA does not translate into protein, testing with nuclear localization of the protein is important to avoid the potential for false positives5

Identifying a patient's AR-V7 status can help predict treatment-driven overall survival in patients with mCRPC

  • Patients who are nuclear AR-V7+ do not respond to AR-targeted therapies but can still benefit from taxane chemotherapy5
  • Patients who are nuclear AR-V7– are likely to live longer on an AR-targeted therapy7

The Oncotype DX AR-V7 Nucleus Detect test is the first and only nuclear-localized AR-V7 test that can predict treatment-driven overall survival in patients with mCRPC7

  1. Antonarakis et al. N Engl J Med. 2014.
  2. Antonarakis et al. Expert Rev Anticancer Ther. 2015.
  3. Maughan et al. Curr Treat Options Oncol. 2015.
  4. Scher et al. JAMA Oncol. 2016.
  5. Scher et al. Eur Urol. 2016.
  6. Antonarakis et al. JAMA Oncol. 2015.
  7. Scher et al. JAMA Oncol. 2018.
Making cancer care smarter.™